biostudies-literatureUnknown8Xu G<b>Aim:</b> The current study aims to investigate the critical role of the focal adhesion kinase (FAK) oncogenic signaling pathway in mediating drug resistance to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (EGFR-TKIs) and evaluate the potential of two novel FAK inhibitors, 10k and 10l, as therapeutic strategies for drug resistant non-small cell lung cancer (NSCLC). <b>Methods:</b> EGFR-TKI resistance in NSCLC cells was developed via stepwise drug selection. Kinases/polymerase chain reaction (PCR) arrays identified key resistance determinants, while reverse transcription quantitative polymerase chain reaction (RT-qPCR), enzyme-linked immunosorbent assay (ELISA), and immunohistochemistry evaluated FAK messenger RNA and phosphorylation levels. Antitumor activities wereCancer drug resistance (Alhambra, Calif.)57https://www.ebi.ac.uk/biostudies/studies/S-EPMC12635985biostudies-literatureNovel FAK inhibitors suppress tumor growth and reverse EGFR-TKI resistance in non-small cell lung cancer.PMC12635985Pecoraro CCavazzoni ADiana PAssaraf YGVahabi MGiovannetti ETiseo MLagrasta CAMXu GCarbone DDeng DZucali PACascioferro SMAvan AFiuji HPeters GJfalseNovel FAK inhibitors suppress tumor growth and reverse EGFR-TKI resistance in non-small cell lung cancer.<b>Aim:</b> The current study aims to investigate the critical role of the focal adhesion kinase (FAK) oncogenic signaling pathway in mediating drug resistance to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (EGFR-TKIs) and evaluate the potential of two novel FAK inhibitors, 10k and 10l, as therapeutic strategies for drug resistant non-small cell lung cancer (NSCLC). <b>Methods:</b> EGFR-TKI resistance in NSCLC cells was developed via stepwise drug selection. Kinases/polymerase chain reaction (PCR) arrays identified key resistance determinants, while reverse transcription quantitative polymerase chain reaction (RT-qPCR), enzyme-linked immunosorbent assay (ELISA), and immunohistochemistry evaluated FAK messenger RNA and phosphorylation levels. Antitumor activities were2025-01-01T00:00:00Z20252026-06-05T17:33:10.865Z2026-05-19T03:11:52.53ZS-EPMC126359854128194310.20517/cdr.2025.139